| Biomarker ID | 101 |
| PMID | 16177248 |
| Year | 2005 |
| Biomarker | bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(RPL22):-Cap-dependent translation initiation,Cytoplasmic ribosomal proteins,Influenza viral RNA transcription and replication, Influenza infection,Translation |
| Experiment | Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | 119 patients with prostate cancer and 138 controls which were equally divided into training and testing. An independent validation set of 128 samples (60 PCA and 68 controls) was also included |
| Senstivity | Training: 88.1% Validation: 81.6% |
| Specificity | Traning: 97.1% Validation: 88.2% |
| AUC | Validation: 0.93 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Phage-protein microarray |
| Clinical | No |
| Remarks | Of the 22 phage peptides identified in this study, 17 are not present in peptide stretches in known proteins. These 17 peptides may be weakly homologous to known proteins or may have no distinct homology to the primary sequences of known proteins and thus may be “mimotopes†|
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | BRD2, EIF4G1, RPL22, RPL13a |